Skip to content

Feasibility study on the value of PET/MRI compared to PET/CT in oncological patients with a molecularly oriented individualized therapy concept

Feasibility study on the value of PET/MRI compared to PET/CT in oncological patients with a molecularly oriented individualized therapy concept - MTB_PET/fMRI (PET/MR_Tü-021)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00024032
Enrollment
50
Registered
2021-01-25
Start date
2021-02-10
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C00-C97

Interventions

Group 1: Cancer-patients of which the diagnostic and therapeutic management was discussed in the Molecular (Tumor) Board (MTB) of the University Hospital Tübingen. For the patients, a PET/CT examinati

Sponsors

Universitätsklinikum Tübingen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Presence of a tumor disease and presentation of the patient in the Molecular Tumor Board (MTB) of the University Hospital Tübingen • Performing a PET/CT based on a clinical indication (MTB) • The patient tolerates about 60 minutes of lying in the tomograph • Age =18 years • Written consent from the patient

Exclusion criteria

Exclusion criteria: • Pregnant / breastfeeding women • Presence of non-MR compatible implants or any kind of metal in and on the body • Patients who report a hearing impairment or an increased sensitivity to loud noises • Patients with limited temperature sensation • Claustrophobia • Limited ability to give consent • Obesity with a body weight of> 150 kg • No consent to the communication of incidental findings

Design outcomes

Primary

MeasureTime frame
Collection of 50 tumor patient-related image data sets, consisting of morphological and functional PET/MRI image data of the primary tumor. The image data are correlated with existing corresponding histopathological and molecular biological information with the aim of developing image-based marker sets for molecular tumor characterization.

Secondary

MeasureTime frame
• Tumor subtyping based on multiparametric image data with regard to prognosis and prediction factors such as receptor status, TNM grading • Correlation and voxel-by-voxel analysis of the PET/MRI data sets with corresponding molecular (bio) markers with the aim of mapping three-dimensional "maps" of various functional and morphogenetic parameters • Development and clinical application of machine learning approaches, e.g. for texture analysis

Countries

Germany

Contacts

Public ContactFerdinand Seith

Radiologische Universitätsklinik Tübingen Diagnostische & Interventionelle Radiologie

ferdinand.seith@med.uni-tuebingen.de07071-29-68627

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026